Company / Cash & Equivalents
Humana Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$4.2B
FY2025
5-year range
$2.2B / $5.1B
FY2021-FY2025
Trend
+89.1%
vs FY2024
Sector context
#11 of 148
Health Care
What the data says
Among 148 Health Care companies, Humana is in the top 7% for cash & equivalents. Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $4.2B.
Based on SEC 10-K filings.
$4.2B in FY2025 with a 5-year CAGR of -2.1%. Top quartile in the Health Care sector.
Declined from $4.7B to $4.2B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -6.0%
- 5-Year CAGR
- -2.1%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 148This company $4.2B Sector average $1.2B
▼
+256.9% above sector average
Key checks
Key Insights
- 5-year CAGR of -2.1%, indicating a declining trend.
- In FY2025, cash & equivalents increased 89.1% year-over-year.
- Ranks #11 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 3.80 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.2B | +89.1% |
| FY2024 | $2.2B | -52.7% |
| FY2023 | $4.7B | -7.3% |
| FY2022 | $5.1B | +49.1% |
| FY2021 | $3.4B | -27.4% |
| FY2020 | $4.7B | +15.3% |
| FY2019 | $4.1B | +73.0% |
| FY2018 | $2.3B | -8.9% |
| FY2017 | $2.6B | -33.7% |
| FY2016 | $3.9B | +240.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026